Effect of liraglutide 3.0 mg on eating behavior in patients with obesity

Introduction. One of the objectives of weight loss in obesity is to prevent metabolic disorders associated with it. An important component in the maintenance of the achieved results is a change of eating behavior.

Goal: to study the effect of liraglutide 3.0 mg on the dynamics of metabolic parameters and eating behavior in patients with obesity. Materials and methods. The study enrolled 42 obese patients in whom anthropometric parameters, metabolic parameters, and eating behavior were assessed with Dutch Eating Behavior Questionnaire (DEBQ). Patients were divided into 2 groups, one of which received liraglutide 3.0 mg with lifestyle modification for 3 months. The other group was recommended to receive only lifestyle modification. The participants were re-examined after 3 months.

Results and discussion. in the liraglutide group in addition to a significant decrease in body weight, BMI and waist circumference, there was a statistical trend toward lower glucose, insulin and HOMA-IR levels. When comparing the dynamics of parameters between the groups, Д body weight, BMI and glucose in the liraglutide group were significantly superior. In reassessment of eating behavior after 3 months of treatment, no statistically significant differences were found with the initial severity of restrictive, emotional, and/or external types in both groups and, despite a more pronounced decrease in body weight in the liraglutide group, between them.

Conclusions: Three months of isolated lifestyle modification and/or its combination with liraglutide 3.0 mg is not sufficient to make a lasting change in eating behavior. However, considering that obesity is a chronic and relapsing disease, the need for eating behavior correction remains relevant to prevent disease recurrence. This substantiates the need for more long-term intervention in obesity, including drug therapy.

1. Dedov I.I., Melnichenko G.A., Shestakova M.V., Troshina E.A., Mazurina N.V., Shestakova E.A. et al. Russian National Clinical Recommendations for Morbid Obesity Treatment in Adults. 3rd Revision (Morbid Obesity Treatment in Adults). Ozhireniye i metabolizm = Obesity and Metabolism. 2018;15(1):53-70. (In Russ.) doi: 10.14341/omet2018153-70.

2. Yumuk V., Tsigos C., Fried M., Schindler K., Busetto L., Micic D. et al. European Guidelines for Obesity Management in Adults. Obesity Facts. 2015;8(6):402-424. doi: 10.1159/000442721.

3. Freedman D.M., Ron E., Ballard-Barbash R., Doody M.M., Linet M.S. Body Mass Index and All-Cause Mortality in a Nationwide US Cohort. Int J Obes (Lond). 2006;30(5):822-829. doi: 10.1038/sj.ijo.0803193.

4. Azagba S., Sharaf M.F. Eating Behavior and Obesity in Canada: Evidence from Panel Data. J Prim Care Community Health. 2012;3(1):57-64. doi: 10.1177/2150131911417445.

5. Shlyakhto E.V., Nedogoda S.V., Konradi A.O., Baranova E.I., Fomin V.V., Vertkin A.L., Chumakova G.A. The Concept of Novel National Clinical Guidelines on Obesity. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2016;(4):7-13. (In Russ.) doi: 10.15829/1560-4071-2016-4-7-13.

6. Van Strien T. Causes of Emotional Eating and Matched Treatment of Obesity. Curr Diab Rep. 2018;18(6):35. doi: 10.1007/s11892-018-1000-x.

7. Velapati S.R., Shah M., Kuchkuntla A.R., Abu-Dayyeh B., Grothe K., Hurt R.T., Mundi M.S. Weight Regain after Bariatric Surgery: Prevalence, Etiology, and Treatment. Curr Nutr Rep. 2018;7(4):329-334. doi: 10.1007/s13668-018-0243-0.

8. Dedov I.I., Shestakova M.V., Melnichenko G.A., Mazurina N.V., Andreeva E.N., Bondarenko I.Z. et al. Interdisciplinary Clinical Practice Guidelines “Management of Obesity and Its Comorbidities”. Ozhireniye i metabolizm = Obesity and Metabolism. 2021;18(1):5-99. (In Russ.) doi: 10.14341/omet12714.

9. Pi-Sunyer X., Astrup A., Fujioka K., Greenway F., Halpern A., Krempf M. et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. doi: 10.1056/NEJMoa1411892.

10. Le Roux C.W., Astrup A., Fujioka K., Greenway F., Lau D.C.W., van Gaal L. et al. 3 Years of Liraglutide versus Placebo for Type 2 Diabetes Risk Reduction and Weight Management in Individuals with Prediabetes: A Randomised, Double-Blind Trial. Lancet. 2017;389(10077):1399-1409. doi: 10.1016/S0140-6736(17)30069-7.

11. Kolotkin R.L., Fujioka K., Wolden M.L., Brett J.H., Bjorner J.B. Improvements in Health-Related Quality of Life with Liraglutide 3.0 mg Compared with Placebo in Weight Management. Clin Obes. 2016;6(4):233-242. doi: 10.1111/cob.12146.

12. Kolotkin R.L., Smolarz B.G., Meincke H.H., Fujioka K. Improvements in Health-Related Quality of Life over 3Years with Liraglutide 3.0 mg Compared with Placebo in Participants with Overweight or Obesity. Clin Obes. 2018;8(1):1-10. doi: 10.1111/cob.12226.

13. De Boer S.A., Lefrandt J.D., Petersen J.F., Boersma H.H., Mulder D.J., Hoogenberg K. The Effects of GLP-1 Analogues in Obese, Insulin-Using Type 2 Diabetes in Relation to Eating Behaviour. Int J Clin Pharm. 2016;38(1):144-151. doi: 10.1007/s11096-015-0219-8.

14. Lean M.E., Han T.S., Morrison C.E. Waist Circumference as a Measure for Indicating Need for Weight Management. BMJ. 1995;311(6998): 158-161. doi: 10.1136/bmj.311.6998.158.

15. Van Strien T., Frijters J.E.R., Bergers G.P.A., Defares P.B. The Dutch Eating Behavior Questionnaire (DEBQ) for Assessment of Restrained, Emotional, and External Eating Behavior. Int J Eat Disord. 1986;5(2):295-315. doi: 10.1002/1098-108X(198602)5:2<295::AID-EAT2260050209>3.0.CO;2-T.

16. Durrer Schutz D., Busetto L., Dicker D., Farpour-Lambert N., Pryke R., Toplak H. et al. European Practical and Patient-Centred Guidelines for Adult Obesity Management in Primary Care. Obes Facts. 2019;12(1): 40-66. doi: 10.1159/000496183.

17. Rebrova O.Yu. Statistical Analysis of Medical Data. Application of STATISTICA Software. Moscow: Media Sfera; 2003. 312 p. (In Russ).

18. Le Roux C., Lau D.C.W., Fujioka K., Caterson I.D., Cancino A.P., Jensen C.B., Lean M.E.J. The Impact of Gastrointestinal Adverse Events on Weight Loss with Liraglutide 3.0 mg as Adjunct to a Diet and Exercise Program. EASD Virtual Meeting. 2015. Available at: https://easddistribute.m-anage.com/from.storage?image=GeagBqeymuldevRFpCasKa2aA9hkkBMRjyfRwTulOEq z2Poilm0D3rEgZMCbj%2Fx0X97Vi3yHe%2Fr65NzlNL%2FJpA%3D%3D.

19. Berrington de Gonzalez A., Hartge P., Cerhan J.R., Flint A.J., Hannan L., MacInnis R.J. et al. Body-Mass Index and Mortality among 1.46 Million White Adults. N Engl J Med. 2010;363(23):2211-2219. doi: 10.1056/NEJMoa1000367.

20. Voznesenskaya T.G., Vakhmistrov A.V. Clinical and Psychological Analysis of Eating Disorders in Obesity. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2001;101(12):19-24. (In Russ).

21. Vakhmistrov A.V. Clinical and Psychological Analysis of Various Forms of Emotiogenic Eating Behavior. Al'manakh klinicheskoy meditsiny = Almanac of Clinical Medicine. 2001;(4):127-130. (In Russ) Available at: https://elibrary.ru/item.asp?id=9464737.

22. Volkova G.E., Romantsova T.I., Voznesenskaya T.G., Roik O.V. Eating Behavior in Obese Patients. Ozhireniye i metabolism = Obesity and Metabolism. 2007;4(2):17-21. (In Russ) doi: 10.14341/2071-8713-5158.